In conclusion, we have utilized an integrated strategy which combines cell‐free, cellular, and in silico assays for reducing a library of 664 small molecules to 9 unique PARP‐1 inhibitors for further development in the treatment of prostate cancer. This evidence concerns the gene PARP1 and prostate carcinoma.